


Q1 Business review

January–March 2026



DETECTION TECHNOLOGY PLC BUSINESS REVIEW JANUARY-MARCH 2026

Detection Technology Q1 2026: Growth in all business applications and markets

January-March 2026 highlights

- Net sales increased by 13.5% to EUR 25.3 million (22.2)
- Net sales of Americas increased by 32.7% to EUR 1.2 million (0.9)
- Net sales of APAC (Asia-Pacific) increased by 10.1% to EUR 17.6 million (16.0)
- Net sales of EMEIA (Europe, Middle East, India and Africa) increased by 20.7% to EUR 6.5 million (5.4)
- Net sales of industrial applications increased by 23.5% to EUR 4.6 million (3.8)
- Net sales of medical applications increased by 15.9% to EUR 12.6 million (10.8)
- Net sales of security applications increased by 5.3% to EUR 8.1 million (7.7)
- Operating profit (EBITA) increased to EUR 2.4 million (1.4)
- Operating margin (EBITA-%) increased to 9.3% of net sales (6.3%)
- Return on net assets (RONA, 12-month rolling) was 23.0% (33.9%)

(Figures in brackets refer to the corresponding period of the previous year.)

Business outlook

Detection Technology expects total net sales to grow year-on-year in Q2 and Q3 2026.

The geopolitical situation, new U.S. import tariffs, material shortages, and price competition especially in China create uncertainty.

Detection Technology aims to increase its sales by at least 10% per annum and to achieve an operating margin (EBITA) of 15% in the medium term.

President and CEO, Hannu Martola:

"Q1 was strong and largely in line with our expectations. Total net sales grew at a double-digit rate, despite continued headwinds from exchange rates. Sales developed positively across all key applications and in all geographical regions. Sales in the EMEIA region reached a record level, and growth in the Americas was strong. It was encouraging to see strong demand for industrial line scanning solutions also in China. Particularly notable was the growth in security sales, which we expect to strengthen further.

Medical sales continued to grow at a double-digit rate, driven by CT (computed tomography) solutions. Demand was strong among both OEMs and small and medium-sized customers. The material shortages that hindered deliveries in the previous year have eased during the review period thanks to our proactive measures.

Security application sales developed well in both the EMEIA region and the Americas. In EMEIA, performance was driven by demand for aviation security CT as well as detector solutions for cargo inspection due to intensified border control measures. In the Americas, growth was fueled by aviation-related line scan solutions. However, overall sales were adversely affected by the security market in China, where equipment renewals have not yet begun.

Sales of line scan solutions for industrial applications grew strongly across all regions, primarily driven by the food industry. The growth in flat panel detectors (TFT) sales continued and is expected to strengthen, particularly in the battery and defense industries.

Our profitability was impacted by the product mix. We have increased inventory buffers as part of our risk management to ensure material availability and delivery capability in an uncertain operating environment.

We advanced our business in line with our new DT2030 strategy. The higher-integration AIDA detector system was commercialized, and the first customer deliveries were successfully completed. In addition, we strengthened our medical CT product portfolio by launching the X-ACE HS product family, which is AIDA compatible and has been well received in the market.

We expect total net sales in Q2 to grow. Sales in medical and security applications are expected to increase. Industrial sales are expected to continue growing quarter-on-quarter but decline year-on-year. Sales in APAC, EMEIA, and the Americas are expected to grow. We expect total net sales to grow in Q3 of 2026."

Key figures

(EUR 1,000)	1-3/2026	1-3/2025	1-12/2025
Net sales	25,264	22,249	101,023
Change in net sales, %	13.5%	-2.0%	-6.0%
EBITA	2,351	1,399	9,255
EBITA, %	9.3%	6.3%	9.2%
R&D costs	2,773	2,634	11,266
R&D costs, % of net sales	11.0%	11.8%	11.2%
Cash flow from operating activities	-3,418	1,425	3,885
Net interest-bearing debt at end of period	-16,820	-28,492	-20,473
Investments	409	390	2,965
Return on net assets (RONA, 12-month rolling), %	23.0%	33.9%	20.4%
Gearing, %	-21.7%	-38.2%	-26.1%
Earnings per share, EUR	0.13	0.05	0.44
Earnings per share (diluted), EUR	0.13	0.05	0.44
Number of shares at the end of the period	14,655,630	14,655,630	14,655,630
Weighted average number of shares outstanding	14,655,630	14,655,830	14,655,680
Weighted average number of shares outstanding, diluted	14,655,630	14,660,256	14,656,787

The development of net sales

Despite currency fluctuations, Detection Technology's total net sales increased by 13.5% (-2.0%) and amounted to EUR 25.3 (22.2) million in Q1 2026. Net sales grew across all main applications and in all geographical areas.

Medical application sales increased at a double-digit rate, driven by the APAC region. Demand for CT solutions was strong among both OEM customers and small and medium-sized customers, and material shortages did not impact deliveries due to inventory buffers. Security application sales increased in both the EMEIA region and the Americas. In EMEIA, performance was supported by demand for aviation CT solutions as well as detector solutions for cargo inspection related to strengthened border control, and in the Americas by aviation line scan solutions. Total net sales of security applications were negatively impacted by the Chinese market, where the renewal of the aviation installed base to CT systems has not yet commenced. Sales of line scan solutions for industrial applications grew strongly across all regions, mainly driven by the food industry, and in addition, TFT sales increased.

The APAC business unit's net sales increased by 10.1% (2.1%) and were EUR 17.6 (16.0) million. The EMEIA business unit's net sales increased by 20.7% (-12.2%) and were EUR 6.5 (5.4) million. The Americas business unit's net sales increased by 32.7% (-3.9%) and were EUR 1.2 (0.9) million. APAC accounted for 69.6% (71.8%) of the company's total net sales, EMEIA for 25.9% (24.3%) and the Americas for 4.6% (3.9%).

Net sales of medical applications increased by 15.9% (13.7%) and were EUR 12.6 (10.8) million. Net sales of security applications increased by 5.3% (-20.0%) and were EUR 8.1 (7.7) million. Net sales of industrial applications increased by 23.5% (4.2%) and were EUR 4.6 (3.8) million. Medical applications accounted for

49.7% (48.7%) of total net sales, security applications for 32.0% (34.4%) and industrial applications for 18.4% (16.9%).

The share of the five largest customers in total net sales was 57.0% (61.5%).

NET SALES BY BUSINESS UNITS

(EUR 1,000)	1-3/2026	1-3/2025	Change, %	1-12/2025
Americas	1,156	871	32.7%	5,155
APAC	17,576	15,969	10.1%	70,380
EMEIA	6,532	5,410	20.7%	25,488
TOTAL	25,264	22,249	13.5%	101,023

NET SALES BY MAIN APPLICATIONS

(EUR 1,000)	1-3/2026	1-3/2025	Change, %	1-12/2025
Industrial	4,638	3,754	23.5%	18,621
Medical	12,554	10,832	15.9%	46,678
Security	8,073	7,664	5.3%	35,724
TOTAL	25,264	22,249	13.5%	101,023

Half-yearly report 2026

Detection Technology will publish the half-yearly report on 6 August 2026.

UNAUDITED BUSINESS REVIEW 1.1.-31.3.2026

ACCOUNTING PRINCIPLES

This unaudited business review for the period 1.1.-31.3.2026 has been prepared according to Finnish Accounting Standards (FAS).

CONSOLIDATED INCOME STATEMENT (FAS)

(EUR 1,000)	1-3/2026	1-3/2025	1-12/2025
Net sales	25,264	22,249	101,023
Other operating income	48	282	668
Materials and services	-13,812	-12,295	-55,781
Personnel expenses	-6,031	-5,766	-23,710
Depreciations	-393	-454	-1,700
Other operating expenses	-2,725	-2,617	-11,244
EBITA	2,351	1,399	9,255
Amortizations	-282	-282	-1,129
Financial income and expenses	188	-241	-719
Profit before taxes	2,257	876	7,407
Income taxes	-306	-185	-913
Minority interest	-11	-15	-53
Profit for the reporting period	1,940	676	6,440

CONSOLIDATED BALANCE SHEET (FAS)

(EUR 1,000)	31.3.2026	31.3.2025	31.12.2025
ASSETS			
NON-CURRENT ASSETS			
Intangible assets	9,803	10,964	10,097
Tangible assets	4,186	4,251	4,045
Investments	1,612	11	1,690
TOTAL NON-CURRENT ASSETS	15,602	15,226	15,832
CURRENT ASSETS			
Inventories	35,961	22,782	29,172
Non-current receivables	471	414	449
Current receivables	33,301	29,138	33,674
Cash and cash equivalents	23,145	28,973	24,979
TOTAL CURRENT ASSETS	92,878	81,308	88,274
TOTAL ASSETS	108,480	96,534	104,106
EQUITY AND LIABILITIES			
EQUITY			
Share capital	80	80	80
Share premium account	5,130	5,130	5,130
Invested non-restricted equity fund	28,405	28,405	28,405
Retained earnings	41,657	40,045	38,133
Profit for the financial period	1,940	676	6,440
TOTAL EQUITY	77,212	74,336	78,189
Minority interest	252	203	232
LIABILITIES			
Current liabilities	31,016	21,995	25,685
TOTAL LIABILITIES	31,016	21,995	25,685
TOTAL EQUITY AND LIABILITIES	108,480	96,534	104,106

CONSOLIDATED CASH FLOW STATEMENT (FAS)

(EUR 1,000)	1-3/2026	1-3/2025	1-12/2025
Cash flow from operations			
Operating profit	2,069	1,117	8,126
Depreciations	675	736	2,829
Other non-cash business activities	268	-79	-1,541
Change in working capital	-6,209	278	-4,297
Financial income and expenses	126	23	-29
Income taxes paid	-347	-650	-1,203
Cash flow from operations	-3,418	1,425	3,885
Cash flow from investments			
Investments in intangible and tangible assets	-409	-390	-1,598
Payment for shares in subsidiaries and associated undertakings	0	0	-1,367
Cash flow from investments	-409	-390	-2,965
Free cash flow	-3,827	1,035	920
Cash flow from financing			
Change in current loans	1,640	0	4,042
Dividend paid	0	0	-7,328
Cash flow from financing	1,640	0	-3,286
Change in cash and cash equivalents			
Cash and cash equivalents at the beginning of the period	24,979	28,266	28,266
Foreign exchange rate effect	353	-328	-920
Cash and cash equivalents at the end of the period	23,145	28,973	24,979
Change in cash and cash equivalents	-2,187	1,035	-2,367
Change in working capital			
Change in current receivables	1,376	3,063	-1,851
Change in inventories	-5,832	-669	-7,594
Change in current liabilities	-1,753	-2,116	5,147
Change in working capital	-6,209	278	-4,297

STATEMENT OF EQUITY CHANGES

(EUR 1,000)	Share capital	Share premium	Invested unrestricted equity fund	Retained earnings	Profit for the period	Total
Equity 1.1.2026	80	5,130	28,405	44,573	0	78,189
Dividend paid	0	0	0	-4,397	0	-4,397
Conversion differences	0	0	0	1,480	0	1,480
Profit for the period	0	0	0	0	1,940	1,940
Equity 31.3.2026	80	5,130	28,405	41,657	1,940	77,212
Equity 1.1.2025	80	5,130	28,405	48,746	0	82,361
Dividend paid	0	0	0	-7,328	0	-7,328
Conversion differences	0	0	0	-1,373	0	-1,373
Profit for the period	0	0	0	0	676	676
Equity 31.3.2025	80	5,130	28,405	40,045	676	74,336
Equity 1.1.2025	80	5,130	28,405	48,746	0	82,361
Dividend paid	0	0	0	-7,328	0	-7,328
Conversion differences	0	0	0	-3,296	0	-3,296
Adjustments to retained earnings	0	0	0	11	0	11
Profit for the period	0	0	0	0	6,440	6,440
Equity 31.12.2025	80	5,130	28,405	38,133	6,440	78,189

Espoo 22 April 2026

Board of Directors
Detection Technology Plc

CALCULATION OF KEY FINANCIAL RATIOS

EBITA	= Operating profit (EBIT) - Amortizations
Change in net sales, %	= (Net sales - Previous financial year's net sales) / Previous financial year's net sales x 100
EBITA, %	= EBITA / Net sales x 100
Net interest-bearing debt	= Interest-bearing liabilities - Cash and cash equivalents
Return on net assets (RONA), %	= EBITA (12 months, excluding NRI) / (Equity + Net interest-bearing debt - Goodwill (average 12 months)) x 100
Gearing, %	= (Interest-bearing liabilities - Cash and cash equivalents) / Equity x 100
Earnings per share, EUR	= Profit for the reporting period / Weighted average number of shares outstanding
Earnings per share (diluted), EUR	= Profit for the reporting period / Weighted average number of shares outstanding, diluted



www.deetee.com